Literature DB >> 17579189

Proteasome inhibitor bortezomib-induced apoptosis in natural killer (NK)-cell leukemia and lymphoma: an in vitro and in vivo preclinical evaluation.

Lijun Shen, Wing-Yan Au, Tianhuan Guo, Kai-Yau Wong, Michelle L Wong, Junjiro Tsuchiyama, Po-Wing Yuen, Yok-Lam Kwong, Raymond H Liang, Gopesh Srivastava.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17579189     DOI： 10.1182/blood-2007-02-072900

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  Large granular lymphocyte disorders: new etiopathogenetic clues as a rationale for innovative therapeutic approaches.

Authors:  Renato Zambello; Gianpietro Semenzato
Journal:  Haematologica       Date:  2009-10       Impact factor: 9.941

Review 2.  Therapeutic Options for Aggressive T-Cell Lymphomas.

Authors:  Jennifer K Lue; Anna Kress; Jennifer E Amengual
Journal:  Curr Hematol Malig Rep       Date:  2017-08       Impact factor: 3.952

3.  Bortezomib-based chemotherapy to treat refractory angioimmunoblastic T-cell lymphoma: A case report and review of the literature.

Authors:  Hua-Ping DU; Qian-Qian Yang; Y E Zhang
Journal:  Oncol Lett       Date:  2016-02-09       Impact factor: 2.967

4.  Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma.

Authors:  J Lee; C Suh; H J Kang; B-Y Ryoo; J Huh; Y H Ko; H-S Eom; K Kim; K Park; W S Kim
Journal:  Ann Oncol       Date:  2008-08-09       Impact factor: 32.976

5.  Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity.

Authors:  Xiangling Wang; Astrid Ottosson; Chunyan Ji; Xiaoli Feng; Magnus Nordenskjöld; Jan-Inge Henter; Bengt Fadeel; Chengyun Zheng
Journal:  Haematologica       Date:  2009-02-19       Impact factor: 9.941

Review 6.  Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside.

Authors:  Anthony R Mato; Tatyana Feldman; André Goy
Journal:  Oncologist       Date:  2012-05-07

Review 7.  Treatment Advances in EBV Related Lymphoproliferative Diseases.

Authors:  Kebing Lv; Ting Yin; Min Yu; Zhiwei Chen; Yulan Zhou; Fei Li
Journal:  Front Oncol       Date:  2022-04-19       Impact factor: 5.738

8.  ABC transporters and the proteasome complex are implicated in susceptibility to Stevens-Johnson syndrome and toxic epidermal necrolysis across multiple drugs.

Authors:  Paola Nicoletti; Mukesh Bansal; Celine Lefebvre; Paolo Guarnieri; Yufeng Shen; Itsik Pe'er; Andrea Califano; Aris Floratos
Journal:  PLoS One       Date:  2015-06-25       Impact factor: 3.240

9.  Are T-LGL Leukemia and NK-Chronic Lymphoproliferative Disorder really two distinct diseases?

Authors:  Renato Zambello; Antonella Teramo; Cristina Gattazzo; Gianpietro Semenzato
Journal:  Transl Med UniSa       Date:  2014-02-04

10.  Extranodal natural killer/T-cell lymphoma, nasal type, involving the skin, misdiagnosed as nasosinusitis and a fungal infection: A case report and literature review.

Authors:  Yan Zheng; Jinjing Jia; Wensheng Li; Juan Wang; Qiong Tian; Zhengxiao Li; Jing Yang; Xinyu Dong; Ping Pan; Shengxiang Xiao
Journal:  Oncol Lett       Date:  2014-09-08       Impact factor: 2.967
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.